NEW YORK – Fujirebio and Indian firm Agappe Diagnostics announced on Friday that they have entered into a contract development and manufacturing organization partnership for cartridge-based chemiluminescence immunoassay system reagents and equipment.
Fujirebio will supply the equipment Mispa i60 and i121 and reagent raw materials as part of the deal, while Agappe will develop and manufacture dedicated reagents for the equipment, the companies said in a statement. The analyzers and reagents will be sold under Agappe's brand, and the firms said they plan to launch the products in June 2024.
Financial and other terms were not disclosed. The companies previously signed a supply and license agreement in March 2023.
Agappe is at the "advanced stages" of technical transfer from Fujirebio, which will allow Agappe to manufacture chemiluminescence reagents using Fujirebio's technology and materials, it said. The partnership will involve the phased launches of immunoassays across a variety of diseases, including oncology, thyroid, cardiac, fertility, and infectious diseases, as well as Alzheimer's and neurodegenerative diseases.
"Leveraging the combined strengths of Agappe and Fujirebio, we are committed to introducing high-quality, affordable, and unique chemiluminescence solutions for the country," Agappe Diagnostics Managing Director Thomas John said in a statement. "This partnership symbolizes our dedication to innovation and our pledge to make advanced diagnostic products more accessible to every Indian."
Agappe currently offers clinical chemistry, hematology, immunochemistry, and point-of-care assays.